ArticleJournal of general internal medicine2026
Impact of PREVENT Cardiovascular Risk Equations on Statin Eligibility by Subgroup and Risk Thresholds: A Cross-Sectional Study.
Article in Journal of general internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundReplacing the pooled cohort equations (PCEs) with the Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations for atherosclerotic cardiovascular disease (ASCVD) risk is projected to reduce statin eligibility, prompting discussion of lowering the risk threshold used with PREVENT. The potential impact on statin eligibility in different subgroups is unknown.
objectiveTo assess the impact of replacing PCEs with PREVENT equations on statin eligibility for a real-world population of primary care patients, incorporating social deprivation index (SDI) and lowering the ASCVD risk thresholds for statin eligibility.
designCross-sectional analysis comparing 10-year ASCVD risk scores and statin eligibility using the PCEs and PREVENT equations within a primary care population. Subgroup analyses were conducted by age, sex, and race. Risk thresholds for statin eligibility were varied to assess the effect on eligibility.
participantsAdult patients who visited a Vanderbilt primary care clinic in 2023. MAIN MEASURES: Estimated 10-year ASCVD risk and proportion of patients eligible for statin therapy using the PCEs vs. PREVENT equations. KEY
resultsIn 50,123 patients, the mean 10-year ASCVD risk was significantly lower with PREVENT compared to the PCEs (3.6 vs. 7.5, p < 0.0001). In 36,430 patients not on statins, PREVENT reduced statin eligibility by 78.2%, with the largest reductions in women (82.6%), patients aged 40-49 (97.8%), and Black patients (81.2%). Lowering the statin eligibility threshold from 7.5 to 3% led to a 27.5% overall increase in eligibility rather than 78.2% reduction. However, gaps between subgroups expanded, and younger and Black patients retained relative reductions in eligibility (e.g., 4.7% decrease in statin eligibility among Black patients compared to a 32.7% increase among White patients).
conclusionsIn a real-world primary care population, replacing the PCEs with the PREVENT equations would significantly reduce statin eligibility at the 7.5% threshold. Lowering the risk threshold would increase overall eligibility but disproportionately affect eligibility within certain subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.